Stay updated on TNBC Neoadjuvant and Adjuvant Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the TNBC Neoadjuvant and Adjuvant Pembrolizumab Clinical Trial page.

Latest updates to the TNBC Neoadjuvant and Adjuvant Pembrolizumab Clinical Trial page
- Check6 days agoChange DetectedThe study record metadata now shows revision v3.4.3, replacing the previous v3.4.2.SummaryDifference0.0%

- Check13 days agoChange DetectedAdded a publication reference by Kuemmel et al. about KEYNOTE-522 in Ann Surg Oncol to the Publications section.SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedAdded Revision: v3.4.2. Removed the government funding status notice and the earlier Revision: v3.4.1.SummaryDifference0.1%

- Check41 days agoChange DetectedA new global notice about government funding and operating status has been added to the top of the page, and the version number has been updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedAdded: Show glossary, Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, and Revision: v3.4.0. Deleted: Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.1%

- Check56 days agoChange DetectedA new publication citation was added to the Publications section: Pembrolizumab for Early-Stage Triple-Negative Breast Cancer—KEYNOTE-522 Japan Subgroup Analysis (Cancer Sci. 2026 Jan 14).SummaryDifference0.0%

Stay in the know with updates to TNBC Neoadjuvant and Adjuvant Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TNBC Neoadjuvant and Adjuvant Pembrolizumab Clinical Trial page.